Intellia Therapeutics Inc... (NTLA)
7.21
-0.86 (-10.66%)
At close: Mar 31, 2025, 10:59 AM
-10.66% (1D)
| Bid | 7.21 |
| Market Cap | 746.37M |
| Revenue (ttm) | 60.61M |
| Net Income (ttm) | -543.53M |
| EPS (ttm) | -5.25 |
| PE Ratio (ttm) | -1.37 |
| Forward PE | -1.95 |
| Analyst | Buy |
| Ask | 7.22 |
| Volume | 1,918,916 |
| Avg. Volume (20D) | 3,258,364 |
| Open | 7.69 |
| Previous Close | 8.07 |
| Day's Range | 7.17 - 7.83 |
| 52-Week Range | 7.17 - 28.18 |
| Beta | 1.97 |
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...
Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2016
Employees 403
Stock Exchange NASDAQ
Ticker Symbol NTLA
Website https://www.intelliatx.com
Analyst Forecast
According to 18 analyst ratings, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $40.5, which is an increase of 461.71% from the latest price.
Stock ForecastsNext Earnings Release
Intellia Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-7.09%
Intellia Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
1 month ago
+0.56%
Intellia Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
